BioNTech’s second act: can it transform the fight against cancer? | Curio
News and insights read out for you.
10,000+ audio articles. 50+ world-leading publications.

All in 1 subscription.

Financial Times logo

BioNTech’s second act: can it transform the fight against cancer?

16 mins | Jun 20, 2022
story image
It could transform the pharmaceutical industry. The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven. BioNTech founders Uğur Şahin and Özlem Türeci, who made the best-selling COVID-19 vaccine, want to use their new wealth to fuel an incredible venture: to tailor drugs to each patient’s cancer. Hanna Kuchler investigates.
Get unlimited access free for 7 days, then $6.67/month (billed annually)
Get started